Company Overview - MiniMed Group Inc. is a diabetes management firm that is set to separate from Medtronic Plc and has filed for an initial public offering (IPO) [1][4] - The company has been part of Medtronic for nearly 25 years and offers a full ecosystem of automated insulin pumps, continuous glucose monitors, and smart insulin pens [3] Financial Performance - For the six months ended October 24, MiniMed reported a net loss of $21 million on revenue of $1.5 billion, an improvement from a net loss of $23 million on revenue of $1.3 billion in the same period the previous year [2] - The company generated approximately $2.7 billion in annual revenue for fiscal year 2025, with recent double-digit percentage growth [3] IPO Details - The IPO filing positions MiniMed to potentially debut in early 2026, alongside other companies such as EquipmentShare.com Inc. and Arko Petroleum Corp. [2] - Goldman Sachs Group Inc., Bank of America Corp., Citigroup Inc., and Morgan Stanley are leading the offering, with shares expected to trade on the Nasdaq Global Select Market under the symbol MMED [5] Corporate Structure and Future Plans - Medtronic will retain at least 80.1% of the voting power post-separation, and plans to distribute shares to investors in a tax-efficient manner, potentially as a spin-off [4] - MiniMed intends to use part of the IPO proceeds to repay intercompany debt owed to Medtronic [4]

Core Viewpoint - Medtronic plc has announced the filing of a registration statement for an initial public offering (IPO) of its Diabetes business, which will operate under the name MiniMed, indicating a strategic separation from the parent company [1][2]. Company Overview - Medtronic plc is a leading global healthcare technology company headquartered in Galway, Ireland, with over 95,000 employees across more than 150 countries, focusing on innovative solutions for various health conditions [6]. - The company's mission is to alleviate pain, restore health, and extend life, with a diverse portfolio that includes cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems [6]. Diabetes Business - The Diabetes business at Medtronic aims to enhance diabetes management through advanced technology, including next-generation sensors and intelligent dosing systems, emphasizing customer experience [5]. - The separation of the Diabetes business is expected to be completed through capital markets transactions, with a preferred path being an IPO followed by a split-off [1][8]. IPO Details - MiniMed intends to list its common stock on the Nasdaq Global Select Market under the symbol MMED, although the number of shares and price range for the offering have not yet been determined [2]. - The IPO process will commence after the SEC review, subject to market conditions [2]. Underwriters - Goldman Sachs & Co. LLC, BofA Securities, Citigroup, and Morgan Stanley will serve as active bookrunners for the proposed offering, with additional support from several other financial institutions [4].

Group 1 - MiniMed Group, the diabetes business of Medtronic, has filed for an initial public offering (IPO) in the United States [1]

Core Viewpoint - Nyxoah SA has successfully issued the first tranche of convertible bonds amounting to €22.5 million as part of a larger financing plan of up to €45 million, aimed at supporting its operations and commercialization efforts in treating Obstructive Sleep Apnea (OSA) [1][2]. Group 1: Convertible Bonds Issuance - The first tranche of convertible bonds was issued for a nominal amount of €22.5 million, consisting of 225 bonds with a nominal value of €100,000 each, fully subscribed by Heights Capital Management (HCM) [2]. - A subscription fee of €1.8 million, equivalent to 8.0% of the principal amount, was paid to HCM, satisfied by set-off against the subscription price [2]. - The bonds carry an interest rate of 6.5% per annum and have a three-year maturity with quarterly amortization payments starting February 18, 2026 [3]. Group 2: Amortization and Conversion Rights - HCM has the right to bring forward the payment of up to two amortized payment amounts between scheduled amortization payment dates [4]. - HCM can convert the outstanding principal or any amortized payment amount at any time during the bond's term, with an initial conversion price set at €5.00 [5]. - Payments of amortized amounts can be made in cash or through the issuance of new ordinary shares, with the issue price determined by specific conditions [6]. Group 3: Future Tranche and Conditions - The company has the option to issue a second tranche of convertible bonds for an additional €22.5 million, contingent upon certain conditions being met between July 18, 2026, and August 18, 2026 [8]. - As of December 16, 2025, certain conditions precedent for the second tranche were not met, including daily traded values and market capitalization thresholds [10]. - The second tranche will be issued on similar terms as the first tranche, with the conversion price based on the lowest VWAP of the shares on the closing date [11]. Group 4: Cash Runway and Use of Proceeds - The issuance of the first tranche and the closing of capital increases will extend the company's cash runway into the third quarter of 2026, potentially extending to the first quarter of 2027 if the second tranche is issued [12]. - Net proceeds from the first tranche will be utilized for commercialization activities in the U.S., clinical data gathering, research and development, and general corporate purposes [13].

As filed with the Securities and Exchange Commission on December 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MiniMed Group, Inc. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) Delaware 3841 33-3985981 (I.R.S. Employer Identification Number) 18000 Devonshire St. Northridge, CA 91325 (763) 514-4000 (Address, including zip ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on January 5, 2026 [1]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must file with the Court by January 5, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that during the Class Period, Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary steps for its launch, leading to misleading statements that caused investor damages when the truth emerged [5].

Core Insights - OSR Holdings, Inc. has completed a share exchange with Woori IO Co., Ltd., making Woori IO a wholly-owned subsidiary of OSR Holdings' Korean intermediate holding company, OSRK [1][2] - Woori IO is collaborating with Samsung Electronics on a Proof-of-Concept study in South Korea to gain regulatory approval for its noninvasive blood glucose monitoring technology [2][3] - Following the corporate integration, Woori IO plans to initiate U.S. market development activities, including a clinical trial in collaboration with a prestigious California research university [3][4] Company Overview - OSR Holdings, Inc. is a global healthcare holding company focused on biomedical innovation, with interests in immuno-oncology, regenerative biologics, and medical device technologies [5] - Woori IO specializes in noninvasive biosensing technologies for glucose monitoring, utilizing a proprietary NIRS-based system for accurate and pain-free glucose tracking [6]

Core Viewpoint - STAAR Surgical Company has announced the adjournment of its Special Meeting of Stockholders regarding the Alcon merger agreement, now rescheduled for January 6, 2026, due to Alcon exercising its right under the merger agreement [1]. Company Overview - STAAR Surgical (NASDAQ: STAA) is a leader in implantable phakic intraocular lenses, providing vision correction solutions that can reduce or eliminate the need for glasses or contact lenses [2]. - The company has been focused solely on ophthalmic surgery since 1982 and has sold over 3 million ICLs in more than 75 countries [2]. - STAAR's EVO ICL™ product line offers a minimally invasive procedure for vision correction without removing corneal tissue or the eye's natural crystalline lens [2]. Merger Information - The Special Meeting of Stockholders was originally scheduled for December 19, 2025, and the record date for eligible stockholders remains October 24, 2025 [1]. - Relevant materials regarding the proposed transaction have been filed with the U.S. Securities and Exchange Commission (SEC), including a definitive proxy statement on September 16, 2025 [3].

Core Insights - Pulse Biosciences (PLSE) has received FDA Investigational Device Exemption (IDE) approval to initiate a study for its nPulse Cardiac Catheter Ablation System aimed at treating paroxysmal atrial fibrillation, marking a significant regulatory milestone for the company [1][4] Company Developments - The IDE approval allows PLSE to commence a multicenter clinical trial, the NANOPULSE-AF study, which will enroll up to 145 patients across 30 sites to evaluate the safety and effectiveness of its nsPFA technology [8][9] - PLSE's nsPFA technology is designed to use lower energy and create single-shot lesions, which could simplify workflows and reduce procedure times [10] - The company has a current market capitalization of $966.4 million [6] Clinical and Market Outlook - The FDA IDE approval strengthens PLSE's position in the fast-growing atrial fibrillation ablation market, which is projected to grow from $26.89 billion in 2024 to $65.33 billion by 2033, with a CAGR of 10.44% from 2025 to 2033 [12] - Encouraging clinical data from ongoing European studies, where 150 patients have been enrolled, supports the U.S. study and helps mitigate risks [11] Competitive Positioning - PLSE's differentiated nanosecond pulsed field ablation technology is expected to reduce collateral damage compared to traditional microsecond systems, potentially enhancing safety and procedural efficiency [10][11] - The successful execution of the study could lead to pivotal clinical data that supports regulatory approval and drives physician adoption, establishing PLSE as a next-generation ablation platform [4][11]

Senseonics Holdings ( SENS ) has been developing CGM devices that are far superior to any devices offered by its competitors. Those innovative efforts are yet to yield returns for shareholders. The one major criticismFull-time Equity Analyst and part-time retail investor with a bias for high quality stocks trading at discounted prices. over the past 5 years I've been retail investing and learning more about how the stock market works, following the work of Ben Graham and Joel Greenblatt. Equity Markets are ...